《盈警》玮俊生物科技(00660.HK)料上年度亏损增至介乎5,700万至6,200万

阿斯达克财经
16 Dec 2024

玮俊生物科技(00660.HK) 发盈警,预料截至2024年6月30日止年度将录得综合净亏损介乎5,700万至6,200万元,对比2023年同期净亏损为约1,000万元,净亏损增加归因于期内毛利减少,以及录得物业、厂房及设备减值亏损。(gc/a)(港股报价延迟最少十五分钟。)

过往派息
公布日期派息事项派息内容
2024/02/29中期业绩无派息
2023/09/29末期业绩无派息
2023/02/28中期业绩无派息
2023/01/10特别业绩合并:10股合并为1股

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10